Virtual Reality Intervention for Skill Acquisition Support in Autism Spectrum Disorder (ASD)

Autism Spectrum Disorder Clinical Trial

Official title:

A Randomized Controlled Phase II Study to Assess the Efficacy of Floreo VR Building Social Connections vs. Active VR Exposure Control as Treatment for Social Skills in Autistic Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05791071
• Other study ID #: Floreo Cortica Protocol
• Status: Completed
• Phase: Phase 2
• Start date: February 15, 2023
• Est. completion date: June 29, 2023

Study information

• Verified date: June 2023
• Source: Floreo, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Randomized Controlled Phase II study to assess the efficacy of Floreo VR (Virtual reality) Building Social Connections as treatment for social skills in children with Autism Spectrum Disorder (ASD)

Description:

In this randomized controlled phase II study, 30 eligible subjects aged 4-10 years old with documented ASD diagnoses will be enrolled and randomized in a 1:1 ratio intervention vs control group.

The Floreo VR Building Social Connections intervention is designed to be administered for 12 weeks, with three treatment visits per week, for a total of 36 treatment visits.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 30
• Est. completion date: June 29, 2023
• Est. primary completion date: June 29, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 4 Years to 10 Years

Eligibility

Inclusion Criteria:

• Males and females aged 4 years to 10 years 11 months of age (up to 11th birthday at randomization).

• Patients or legally authorized representatives must provide written informed consent and be willing and able to comply with study procedures. Participants must provide informed assent as clinically appropriate.

• A diagnosis of autism spectrum disorder on the basis of the clinical judgement of a qualified clinician according to DSM-5 criteria, supported by either the Autism Diagnostic Observation Schedule or the Autism Diagnostic Interview-Revised.

• Participants must receive ABA therapy at Cortica, with scheduled ABA sessions in clinic at least 3 times per week.

• Participants must be able to tolerate VR therapy in the judgement of parent or caregiver and study staff

Exclusion Criteria:

• A history of photosensitive epilepsy, or photoparoxysmal response on electroencephalogram (EEG)

• Active diagnosis of migraine headache or migraine variant (abdominal migraine, cyclic vomiting syndrome), not adequately controlled

• History of balance disorder including vertigo, motion sensitivity, or balance disorder

• Primary sensory impairment (blindness, deafness)

• Motor disorder that would interfere with VR engagement

Related Conditions & MeSH terms

• Autism Spectrum Disorder

Intervention

Device:
• Floreo VR Building Social Connections
Floreo's VR platform consists of a VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) that are seamlessly linked in real time, allowing the therapist (or monitor) to set up lessons, change the interactive environment, and provide live verbal and VR-based guidance, feedback, and rewards to users. The lessons that will be implemented in this intervention are aimed at targeting social skills such as communication, joint attention, and social interactions.
• Sham
This condition will contain the same VR headset and wireless tethered VR screens (iPhones) and tablets (iPads) as the intervention condition, but instead of social skill lessons, only non-intervention, active VR videos such as underwater fish swimming will be shown.

Locations

Country	Name	City	State
United States	Cortica	Thousand Oaks	California

Sponsors (2)

Lead Sponsor	Collaborator
Floreo, Inc.	Cortica

Country where clinical trial is conducted

United States, 

References & Publications (1)

Kanne SM, Mazurek MO, Sikora D, Bellando J, Branum-Martin L, Handen B, Katz T, Freedman B, Powell MP, Warren Z. The Autism Impact Measure (AIM): initial development of a new tool for treatment outcome measurement. J Autism Dev Disord. 2014 Jan;44(1):168-79. doi: 10.1007/s10803-013-1862-3. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	AIM sub-domain scores	The AIM is a 25-item parent questionnaire targeting sensitivity to change of core ASD symptoms. The questionnaire uses a 2-week recall period with items rated on two corresponding 5-point scales (frequency and impact). The items cover distinct sub-domains of ASD symptoms including Repetitive Behavior, Atypical Behavior, Social Reciprocity, and Peer Interaction. A composite score is also calculated.	The AIM takes approximately 30 minutes to complete.
Other	Vineland-3 Adaptive Behavior Composite and sub-domain scores	The Vineland-3 evaluates adaptive behavior in five different domains: Social, Communication, Daily Living Skills, and Motor. In the context of this study, it will be administered using the Comprehensive Interview Form, for which a parent or caregiver is interviewed by a qualified rater familiar with the instrument. Based on the summarized scores in each domain, an Adaptive Behavior Composite (ABC) is also calculated. Items are scored on a scale of 0 (never), 1 (sometimes), or 2 (usually) for the level at which the child can independently perform a skill.	The Vineland-3 Comprehensive Interview Form takes approximately 60-90 minutes to complete
Other	Adverse events related to VR use	Parents or caregivers will be asked about adverse events at the baseline visit (if this is separate from the screening visit), interim visits 1 and 2, and at the end of study visit. The occurrence or absence of AEs, and a description of any AEs, will be recorded on an Adverse Events Form.	5-10 minutes as needed to fill out AE form
Primary	Autism Impact Measure (AIM) Assessment	The AIM is a 25-item parent questionnaire targeting sensitivity to change of core ASD symptoms. The questionnaire uses a 2-week recall period with items rated on two corresponding 5-point scales (frequency and impact). The items cover distinct sub-domains of ASD symptoms including Repetitive Behavior, Atypical Behavior, Social Reciprocity, and Peer Interaction. A composite score is also calculated.	The AIM takes approximately 30 minutes to complete.
Secondary	CARS-2	The CARS-2 is a 15-item rating scale used to identify children with autism and determine overall symptom severity. The scale is completed by a clinician familiar with the assessment of ASD after collecting information by direct interview and observation. The rater will also make use of supplemental collected using an unscored Parent/Caregiver Questionnaire. Only the CARS-2 Standard rating scale will be used for the purposes of this study.	The CARS-3 takes approximately 5-10 minutes to complete after the information needed to make the ratings is collected

External Links

•   Cortica Website
•   Floreo Website